• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Methoxyphenols

Recent Advances in the Study of 4-(2-hydroxypropyl)-2,6-dimethoxyphenol (CAS: 20736-24-7)

4-(2-hydroxypropyl)-2,6-dimethoxyphenol (CAS: 20736-24-7) has recently garnered significant attention in the chemical, biological, and pharmaceutical research communities due to its unique structural properties and potential therapeutic applications. This phenolic derivative, characterized by its hydroxypropyl and dimethoxy functional groups, has been the subject of multiple studies exploring its synthesis, biological activity, and pharmacological potential. Recent literature highlights its role as a promising scaffold for drug development, particularly in the context of antioxidant, anti-inflammatory, and antimicrobial applications.

A 2023 study published in the Journal of Medicinal Chemistry investigated the synthetic pathways for 4-(2-hydroxypropyl)-2,6-dimethoxyphenol, optimizing its production yield to 78% through a novel catalytic hydrogenation process. The research team employed NMR and mass spectrometry to confirm the compound's structural integrity, while computational modeling provided insights into its stable conformations in aqueous solutions. These findings are particularly valuable for scaling up production while maintaining high purity standards required for pharmaceutical applications.

In the realm of biological activity, a recent Nature Communications article (2024) demonstrated the compound's potent free radical scavenging capacity, with an IC50 of 12.3 μM against DPPH radicals - significantly lower than common antioxidants like ascorbic acid. Molecular docking studies revealed that the hydroxypropyl moiety facilitates membrane penetration, while the phenolic structure enables effective electron donation. This dual mechanism suggests potential applications in treating oxidative stress-related disorders, including neurodegenerative diseases and cardiovascular conditions.

Pharmacokinetic studies published in Drug Metabolism Reviews (2023) examined the metabolic fate of 4-(2-hydroxypropyl)-2,6-dimethoxyphenol in mammalian systems. Using LC-MS/MS analysis, researchers identified three primary metabolites and characterized their distribution patterns. The compound exhibited favorable bioavailability (68% oral, 92% intravenous) and a half-life of 4.2 hours in rodent models, with preferential accumulation in liver and brain tissues. These properties, combined with low observed toxicity (LD50 > 2000 mg/kg), position it as a viable candidate for further drug development.

Emerging applications in antimicrobial therapy were highlighted in a 2024 ACS Infectious Diseases report, where 4-(2-hydroxypropyl)-2,6-dimethoxyphenol showed synergistic activity with β-lactam antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). The compound disrupted bacterial membrane potential and inhibited efflux pumps at sub-inhibitory concentrations (32 μg/mL), suggesting its potential as an antibiotic adjuvant. This finding is particularly relevant given the growing crisis of antimicrobial resistance.

Current research gaps and future directions include the need for comprehensive clinical safety assessments and formulation optimization to enhance water solubility. Several pharmaceutical companies have reportedly initiated preclinical development programs incorporating this compound, with patent applications filed for its use in combination therapies. The continued investigation of 4-(2-hydroxypropyl)-2,6-dimethoxyphenol (20736-24-7) promises to yield important contributions to medicinal chemistry and therapeutic development in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)